Characterization of a novel monoclonal antibody candidate that targets bacterial GAPDH and protects neonatal mice from infections caused by Streptococcus pneumoniae or Streptococcus agalactiae
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.00666-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Carolina Fernandes und 11 weiteren Autor:innen. Beteiligte Einrichtung: Immunethep, Biocant Park, Cantanhede, Portugal. Hauptthemen laut MEDLINE: Streptococcus pneumoniae, Streptococcus agalactiae, Antibodies, Monoclonal, Glyceraldehyde-3-Phosphate Dehydrogenases. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union Horizon 2020 research and innovation programme, MOSBRI project under the Trans-National Access (TNA) project.
Abstract (Originalsprache)
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a highly conserved bacterial enzyme essential for glycolysis, yet it also plays important non-metabolic, “moonlighting” roles, including host immunomodulation. Here, we describe the generation and characterization of a monoclonal antibody (mAb01) that targets extracellular GAPDH from Streptococcus agalactiae (GBS) and Streptococcus pneumoniae . Using bio-layer interferometry (BLI) and surface plasmon resonance (SPR), we demonstrate that mAb01 binds with high affinity, exhibiting dissociation constants in the low nanomolar range for both antigens. Functionally, mAb01 significantly improves survival in a neonatal murine model of sepsis caused by either GBS or S. pneumoniae , two relevant neonatal pathogens. The addition of mAb01 to ex vivo cultures of human peripheral blood infected with GBS or S. pneumoniae induced a significant decrease in bacterial replication, further supporting its protective potential. These results provide the first demonstration of a high-affinity anti-GAPDH monoclonal antibody that is effective in both in vivo and ex vivo models of streptococcal infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunethep, Biocant Park, Cantanhede, Portugal.
- ICBAS - Instituto de Ciencias Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal.
- Accelbio: Collaborative Laboratory to Foster Translation and Drug Discovery, Cantanhede, Portugal.
- Plateforme de Biophysique Moléculaire, Institut Pasteur, CNRS UMR3528, Paris, France.
- Serviço de Imuno-hemoterapia, Centro Hospitalar e Universitário de São João, Porto, Portugal.
ORCID-Profile: Carolina Fernandes, Marta Vieira, Patrick England, Pedro Madureira, Pedro Castanheira
Förderung
- European Union Horizon 2020 research and innovation programme
- MOSBRI project under the Trans-National Access (TNA) project
Zitieren
APA
Fernandes, C., Lemos, F., Curado, L., Victor, B. L., Chevreuil, M., Machado, I., Teixeira, S., Koch, M. C., Vieira, M., England, P., Madureira, P., & Castanheira, P. (2026). Characterization of a novel monoclonal antibody candidate that targets bacterial GAPDH and protects neonatal mice from infections caused by Streptococcus pneumoniae or Streptococcus agalactiae. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00666-25
Vancouver
Fernandes C, Lemos F, Curado L, Victor BL, Chevreuil M, Machado I, et al. Characterization of a novel monoclonal antibody candidate that targets bacterial GAPDH and protects neonatal mice from infections caused by Streptococcus pneumoniae or Streptococcus agalactiae. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00666-25
BibTeX
@article{Fernandes2026,
author = {Fernandes, Carolina and Lemos, Filipa and Curado, Liliana and Victor, Bruno L and Chevreuil, Maelenn and Machado, Inês and Teixeira, Sofia and Koch, Maria do Carmo and Vieira, Marta and England, Patrick and Madureira, Pedro and Castanheira, Pedro},
title = {Characterization of a novel monoclonal antibody candidate that targets bacterial GAPDH and protects neonatal mice from infections caused by Streptococcus pneumoniae or Streptococcus agalactiae},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.00666-25}
}
EUVIMED